Disc Medicine (NASDAQ:IRON) Insider Sells $123,675.00 in Stock

Disc Medicine, Inc. (NASDAQ:IRON) insider Rahul Khara sold 1,649 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $123,675.00. Following the completion of the sale, the insider directly owned 52,173 shares in the company, valued at $3,912,975. This trade represents a 3.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Rahul Khara also recently made the following trade(s):

• On Friday, June 26th, Rahul Khara sold 851 shares of Disc Medicine stock. The stock was sold at an average price of $75.00, for a total transaction of $63,825.00.
• On Thursday, June 18th, Rahul Khara sold 7,500 shares of Disc Medicine stock. The stock was sold at an average price of $70.22, for a total transaction of $526,650.00.

Disc Medicine Trading Down 1.8%

Disc Medicine stock traded down $1.36 during trading on Tuesday, hitting $73.14. The company had a trading volume of 729,507 shares, compared to its average volume of 612,517. The stock has a market cap of $2.79 billion, a price-to-earnings ratio of -11.05 and a beta of 0.93. The company has a current ratio of 24.00, a quick ratio of 24.00 and a debt-to-equity ratio of 0.04. Disc Medicine, Inc. has a 1-year low of $40.00 and a 1-year high of $99.50. The company’s 50 day simple moving average is $68.99 and its 200-day simple moving average is $70.77.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($1.65) EPS for the quarter, missing analysts’ consensus estimates of ($1.62) by ($0.03). As a group, analysts expect that Disc Medicine, Inc. will post -6.74 EPS for the current fiscal year.

Institutional Investors Weigh In On Disc Medicine

Several large investors have recently bought and sold shares of IRON. ANTIPODES PARTNERS Ltd purchased a new position in shares of Disc Medicine in the 4th quarter valued at about $33,000. Aster Capital Management DIFC Ltd purchased a new stake in shares of Disc Medicine during the third quarter worth approximately $38,000. KBC Group NV acquired a new stake in Disc Medicine in the fourth quarter valued at approximately $80,000. Persistent Asset Partners Ltd purchased a new position in Disc Medicine in the fourth quarter worth approximately $141,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in Disc Medicine by 36.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,834 shares of the company’s stock worth $146,000 after acquiring an additional 490 shares during the last quarter. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Wedbush reaffirmed an “outperform” rating and issued a $88.00 target price on shares of Disc Medicine in a research report on Wednesday, June 10th. Wall Street Zen raised shares of Disc Medicine from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. Morgan Stanley raised their price objective on shares of Disc Medicine from $80.00 to $85.00 and gave the company an “overweight” rating in a research note on Monday, June 15th. Wells Fargo & Company lifted their price objective on shares of Disc Medicine from $78.00 to $79.00 and gave the company an “overweight” rating in a report on Monday, March 2nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a research note on Monday, April 20th. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $105.80.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.